Accès libre

Rituximab in the treatment of Pembrolizumab induced Myasthenia Gravis

,  et   
11 juil. 2022
À propos de cet article

Citez
Télécharger la couverture

Pembrolizumab is a monoclonal antibody programmed cell death 1 inhibitor that is an established treatment for melanoma and various lung cancers. Whilst an effective treatment option, it is known to have multiple immune related adverse events associated with its use, including neurological complications such as myasthenia gravis. Previous case reports on the treatment of Pembrolizumab induced myasthenia gravis have detailed the difficulty in managing the condition. There is increasing evidence that Rituximab, a monoclonal antibody directed at CD20 antigen B cells may be an effective treatment option for this condition. This case report outlines the successful treatment of a patient with Pembrolizumab induced myasthenia gravis who was managed with Rituximab.

Langue:
Anglais
Périodicité:
2 fois par an
Sujets de la revue:
Médecine, Sciences médicales de base, Sciences médicales de base, autres